GSK has struck a deal worth up to $1.15bn (£950m) to acquire a Massachusetts-based developer of rare cancer therapies, in an attempt to bolster its expanding oncology business.
GSK, Britain’s second-biggest drugmaker behind AstraZeneca, said the acquisition of IDRx, based in Plymouth near Boston, would help it target a “major gap in the current standard of care” related to gastrointestinal cancers.
